JP2015508284A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508284A5 JP2015508284A5 JP2014548019A JP2014548019A JP2015508284A5 JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5 JP 2014548019 A JP2014548019 A JP 2014548019A JP 2014548019 A JP2014548019 A JP 2014548019A JP 2015508284 A5 JP2015508284 A5 JP 2015508284A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- nucleic acid
- homodimeric protein
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 15
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 230000000890 antigenic effect Effects 0.000 claims 9
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 230000008685 targeting Effects 0.000 claims 5
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 4
- 238000006471 dimerization reaction Methods 0.000 claims 4
- 108700019828 Hinge Exons Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002246 oncogenic effect Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578542P | 2011-12-21 | 2011-12-21 | |
| US61/578,542 | 2011-12-21 | ||
| PCT/EP2012/076404 WO2013092875A1 (en) | 2011-12-21 | 2012-12-20 | Vaccines against hpv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508284A JP2015508284A (ja) | 2015-03-19 |
| JP2015508284A5 true JP2015508284A5 (enExample) | 2016-02-18 |
| JP6258864B2 JP6258864B2 (ja) | 2018-01-10 |
Family
ID=47471832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548019A Active JP6258864B2 (ja) | 2011-12-21 | 2012-12-20 | Ｈｐｖに対するワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9901635B2 (enExample) |
| EP (2) | EP2793937B1 (enExample) |
| JP (1) | JP6258864B2 (enExample) |
| KR (1) | KR102057265B1 (enExample) |
| CN (1) | CN104039833B (enExample) |
| AU (1) | AU2012356969B2 (enExample) |
| BR (1) | BR112014015016B1 (enExample) |
| CA (1) | CA2858963C (enExample) |
| DK (1) | DK2793937T3 (enExample) |
| ES (1) | ES2730718T3 (enExample) |
| HU (1) | HUE043361T2 (enExample) |
| IL (1) | IL233217B (enExample) |
| PT (1) | PT2793937T (enExample) |
| RU (1) | RU2644201C2 (enExample) |
| TR (1) | TR201908199T4 (enExample) |
| WO (1) | WO2013092875A1 (enExample) |
| ZA (1) | ZA201404516B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014140176A1 (en) * | 2013-03-15 | 2014-09-18 | Vaccibody As | Targeting vaccines for veterinary use |
| US10286058B2 (en) * | 2014-01-13 | 2019-05-14 | Baylor Research Institute | Vaccines against HPV and HPV-related diseases |
| BR112017002809A2 (pt) * | 2014-08-15 | 2017-12-19 | Genexine Inc | métodos para tratar câncer cervical |
| SG10202001501QA (en) * | 2015-08-20 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Therapeutic hpv18 vaccines |
| KR102833333B1 (ko) | 2016-01-08 | 2025-07-11 | 니코데 테라퓨틱스 에이에스에이 | 치료적 항암 네오에피토프 백신 |
| US12005112B2 (en) | 2017-09-07 | 2024-06-11 | University Of Oslo | Vaccine molecules |
| US12268736B2 (en) | 2017-09-07 | 2025-04-08 | University Of Oslo | Vaccine molecules |
| IL297049A (en) | 2020-04-09 | 2022-12-01 | Nykode Therapeutics ASA | Individualized therapeutic anticancer vaccine |
| PH12022552820A1 (en) | 2020-04-24 | 2024-03-25 | Genexine Inc | Method for treating cervical cancer |
| EP4143210A1 (en) | 2020-05-01 | 2023-03-08 | Nykode Therapeutics ASA | Betacoronavirus prophylaxis and therapy |
| US20240173391A1 (en) | 2021-03-26 | 2024-05-30 | Nykode Therapeutics ASA | Therapeutic combination for treating cancer |
| US20250339509A1 (en) | 2021-05-03 | 2025-11-06 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| EP4337247A1 (en) | 2021-05-10 | 2024-03-20 | Nykode Therapeutics ASA | Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders |
| JP2024518463A (ja) | 2021-05-10 | 2024-05-01 | ナイコード セラピューティクス アルメン アクスイェ セルスカプ | 構築物及び免疫阻害化合物の共発現 |
| WO2022238402A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Tolerance-inducing constructs and composition and their use for the treatment of immune disorders |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| BR112023023260A2 (pt) | 2021-05-10 | 2024-01-30 | Nykode Therapeutics ASA | Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica |
| WO2022238363A1 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases |
| AU2022381515A1 (en) | 2021-11-03 | 2024-05-09 | Adaptive Biotechnologies Corporation | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 |
| WO2024092025A1 (en) | 2022-10-25 | 2024-05-02 | Nykode Therapeutics ASA | Constructs and their use |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| EP1553966B1 (en) | 2002-10-03 | 2012-08-01 | Wyeth Holdings Corporation | Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof |
| EP2862878B1 (en) * | 2003-02-25 | 2022-11-02 | Nykode Therapeutics ASA | Modified antibody |
| PL1576967T3 (pl) * | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| WO2006081323A2 (en) | 2005-01-26 | 2006-08-03 | The Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin |
| WO2011161244A1 (en) * | 2010-06-25 | 2011-12-29 | Vaccibody As | Homodimeric protein constructs |
-
2012
- 2012-12-20 AU AU2012356969A patent/AU2012356969B2/en active Active
- 2012-12-20 HU HUE12809271A patent/HUE043361T2/hu unknown
- 2012-12-20 CN CN201280064089.7A patent/CN104039833B/zh active Active
- 2012-12-20 TR TR2019/08199T patent/TR201908199T4/tr unknown
- 2012-12-20 KR KR1020147020468A patent/KR102057265B1/ko active Active
- 2012-12-20 WO PCT/EP2012/076404 patent/WO2013092875A1/en not_active Ceased
- 2012-12-20 EP EP12809271.5A patent/EP2793937B1/en active Active
- 2012-12-20 EP EP19166523.1A patent/EP3533462A1/en not_active Withdrawn
- 2012-12-20 JP JP2014548019A patent/JP6258864B2/ja active Active
- 2012-12-20 ES ES12809271T patent/ES2730718T3/es active Active
- 2012-12-20 US US14/365,536 patent/US9901635B2/en active Active
- 2012-12-20 CA CA2858963A patent/CA2858963C/en active Active
- 2012-12-20 BR BR112014015016-8A patent/BR112014015016B1/pt active IP Right Grant
- 2012-12-20 PT PT12809271T patent/PT2793937T/pt unknown
- 2012-12-20 RU RU2014129788A patent/RU2644201C2/ru active
- 2012-12-20 DK DK12809271.5T patent/DK2793937T3/da active
-
2014
- 2014-06-18 IL IL233217A patent/IL233217B/en active IP Right Grant
- 2014-06-19 ZA ZA2014/04516A patent/ZA201404516B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508284A5 (enExample) | ||
| RU2014129788A (ru) | Вакцины против hpv | |
| CN108434450B (zh) | 基于铁蛋白纳米颗粒的疫苗及其制备方法 | |
| JP2013532971A5 (enExample) | ||
| Liu et al. | High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture | |
| JP2015119730A5 (enExample) | ||
| JP2012095652A5 (enExample) | ||
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| RU2013103335A (ru) | Конструкции гомодимерных белков | |
| JP2019506175A5 (enExample) | ||
| JP2010166921A5 (enExample) | ||
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| JP2016533332A5 (enExample) | ||
| BRPI0408639A (pt) | molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, método para produzir partìculas semelhantes a vìrus, vacina, composições farmacêuticas, e, métodos para prevenir a infecção por hpv e para induzir uma resposta imune em um animal | |
| JP2015501840A5 (enExample) | ||
| AR045804A1 (es) | Expresion optimizada de l1 del vph45 en levaduras | |
| CN104710515B (zh) | 人乳头瘤病毒l1蛋白突变体及其制备方法 | |
| CN102747047A (zh) | 人乳头瘤病毒型别杂合病毒样颗粒及其制备方法 | |
| JP2012515557A5 (enExample) | ||
| JP2014519817A5 (enExample) | ||
| CN105296521A (zh) | 表达可溶性人乳头瘤病毒16亚型l1蛋白的重组质粒及其表达方法 | |
| JP2014530224A (ja) | ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル | |
| JP2026500600A (ja) | Ｈｐｖ感染関連疾患を予防又は治療するためのポリヌクレオチド分子 | |
| Motevalli et al. | Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo | |
| JP2013531991A5 (enExample) |